Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RAGE-ADC
- Development stage
- Preclinical
- Lead developer
- Swansea University
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
RAGE-ADC (also known as SNIPER) is an antibody-drug conjugate (ADC) targeting the Receptor for Advanced Glycation End products (RAGE), which is highly expressed in several cancers, including ovarian, endometrial, and prostate cancers. Developed by researchers at Swansea University, the ADC consists of an anti-RAGE antibody conjugated to a cytotoxic payload, such as monomethyl auristatin E (MMAE) via a cleavable valine-citrulline (vc) linker, or monomethyl auristatin F (MMAF) via a non-cleavable maleimido caproyl (mc) linker. RAGE-ADC selectively binds to RAGE on cancer cells, leading to internalization and release of the cytotoxic payload, which inhibits tubulin polymerization and induces cell death. It is being investigated for the treatment of gynaecological cancers (such as ovarian and endometrial cancers) and prostate cancer, including in combination with other agents like prokineticin 2 (PROK2) to target both the tumor cells and the tumor microenvironment.
- Other names
- RAGE-targeted ADCRAGE-targeting ADC
02
Targets
AGER (RAGE)
Beyond the preview
Go deeper on RAGE-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAGE-ADC.